Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2010 | 06-2010 | 03-2010 | 12-2009 | 09-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,830 | 5,090 | 14,850 | 5,680 | 8,980 |
| Marketable Securities | 5,990 | 5,990 | 0 | 0 | 0 |
| Other current assets | 340 | 310 | 460 | 120 | 250 |
| TOTAL | $9,160 | $11,390 | $15,310 | $5,800 | $9,230 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | N/A | 750 | N/A |
| Other Non-Current Assets | 10 | 10 | 10 | 10 | 10 |
| TOTAL | $10 | $10 | $10 | $760 | $10 |
| Total Assets | $9,600 | $11,840 | $15,760 | $6,250 | $9,720 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 830 | 320 | 1,120 | 620 | 530 |
| Accrued Expenses | 1,170 | 1,200 | 1,220 | 1,070 | 1,470 |
| Other current liabilities | 4,210 | 3,790 | 6,400 | 3,720 | 1,860 |
| TOTAL | $6,270 | $5,370 | $8,790 | $5,470 | $3,900 |
| Non-Current Liabilities | |||||
| TOTAL | $40 | $30 | $50 | $30 | $80 |
| Total Liabilities | $6,310 | $5,400 | $8,850 | $5,510 | $3,980 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1 | N/A | N/A | N/A | N/A |
| Common Shares | 3 | 3 | 3 | 2 | 2 |
| Retained earnings | -53,910 | -49,770 | -47,630 | -43,750 | -37,600 |
| Other shareholders' equity | 147 | 147 | 147 | 8 | -2 |
| TOTAL | $3,280 | $6,430 | $6,910 | $740 | $5,730 |
| Total Liabilities And Equity | $9,590 | $11,830 | $15,760 | $6,250 | $9,710 |